Introduction: The introduction of biological therapies has revolutionized the treatment of moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor of interleukin-17A, has shown great results in terms of efficacy and safety in both clinical trials and real-world experiences. However, there is a lack of long-term real-world data available for ixekizumab. Methods: We conducted a multicenter real-life study to evaluate the effectiveness and safety of ixekizumab in patients with moderate-to-severe plaque psoriasis. Psoriasis Area and Severity Index score (PASI) was collected at baseline and after 1, 2, 3, 4, and 5 years. The occurrence of any adverse events was recorded at each time point. Results: We enrolled 1096 patients treated with ixekizumab for at least 1 year. At week 52, the percentages of PASI 90 and PASI 100 were 85.04% and 69.07%, respectively. After 5 years of treatment with ixekizumab, out of 145 patients, a PASI 90 response was achieved by 86.90% of patients, while complete skin clearance was reached by 68.28% of patients. We did not observe any new significant safety findings throughout the study period. Conclusion: This study supports the long-term effectiveness and safety of ixekizumab in a real-world setting.
Long-term effectiveness and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: a five-year multicenter retrospective study—IL PSO (Italian Landscape Psoriasis) / M. Valenti, L. Gargiulo, L. Ibba, P. Malagoli, F. Amoruso, A. Balato, F. Bardazzi, M. Burlando, C.G. Carrera, P. Dapavo, V. Dini, F.M. Gaiani, G. Girolomoni, C. Guarneri, C. Lasagni, F. Loconsole, A.V. Marzano, M. Maurelli, M. Megna, D. Orsini, M. Travaglini, A. Costanzo, A. Narcisi. - In: DERMATOLOGY AND THERAPY. - ISSN 2193-8210. - 14:6(2024 Jun), pp. 1649-1657. [10.1007/s13555-024-01182-4]
Long-term effectiveness and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: a five-year multicenter retrospective study—IL PSO (Italian Landscape Psoriasis)
F.M. Gaiani;A.V. Marzano;A. Costanzo;
2024
Abstract
Introduction: The introduction of biological therapies has revolutionized the treatment of moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor of interleukin-17A, has shown great results in terms of efficacy and safety in both clinical trials and real-world experiences. However, there is a lack of long-term real-world data available for ixekizumab. Methods: We conducted a multicenter real-life study to evaluate the effectiveness and safety of ixekizumab in patients with moderate-to-severe plaque psoriasis. Psoriasis Area and Severity Index score (PASI) was collected at baseline and after 1, 2, 3, 4, and 5 years. The occurrence of any adverse events was recorded at each time point. Results: We enrolled 1096 patients treated with ixekizumab for at least 1 year. At week 52, the percentages of PASI 90 and PASI 100 were 85.04% and 69.07%, respectively. After 5 years of treatment with ixekizumab, out of 145 patients, a PASI 90 response was achieved by 86.90% of patients, while complete skin clearance was reached by 68.28% of patients. We did not observe any new significant safety findings throughout the study period. Conclusion: This study supports the long-term effectiveness and safety of ixekizumab in a real-world setting.File | Dimensione | Formato | |
---|---|---|---|
13555_2024_Article_1182.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
550.36 kB
Formato
Adobe PDF
|
550.36 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.